<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129568</url>
  </required_header>
  <id_info>
    <org_study_id>01F1701003</org_study_id>
    <nct_id>NCT03129568</nct_id>
  </id_info>
  <brief_title>Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy</brief_title>
  <acronym>TICAP-DCM</acronym>
  <official_title>A Randomized Phase 1 Trial of Cardiac Progenitor Cell Therapy in Children With Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Okayama University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Okayama University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1 randomized-controlled study to determine the procedural feasibility and safety and
      preliminary efficacy of intracoronary infusion of cardiosphere-derived cells (CDCs) in
      patients with dilated cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial consists of 2 studies. Seven consecutive patients will be enrolled to a phase 1a
      study to verify the procedural feasibility and safety, followed by a phase 1b study to
      randomly assign 24 patients in a 1:1 ratio to the CDC infusion group and the control arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Transcoronary infusion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Major Cardiac Adverse Events Related to Transcoronary Infusion of CDCs.</measure>
    <time_frame>6 months after CDC treatment</time_frame>
    <description>Assessment of major adverse cardiac events include death, sustained/symptomatic ventricular tachycardia, aggravation of heart failure, acute coronary syndrome, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Ejection Fraction</measure>
    <time_frame>6 months after protocol treatment</time_frame>
    <description>To determine the changes in cardiac function by ejection fraction with cardiac MRI evaluation in CDC-treated participants compared with controls from baseline to 6 months of follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>CDC infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDCs infusion by coronary intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation (Control group)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Coronary angiogram without placebo infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CDC infusion</intervention_name>
    <description>Injection of CDCs (0.3 million per kg of body weight).</description>
    <arm_group_label>CDC infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as dilated cardiomyopathy.

          -  Patients aged under 18 years old.

          -  Cardiac ejection fraction &lt; 40%.

        Exclusion Criteria:

          -  Contradiction to cardiac magnetic resonance imaging.

          -  Cardiogenic shock.

          -  A patient with unstoppable extracorporeal circulation.

          -  A patient with lethal, uncontrollable arrhythmia.

          -  A patient with a complication of coronary artery disease.

          -  A patient with a complication of brain dysfunction due to circulatory failure.

          -  A patient with malignant neoplasm.

          -  A patient with a complication of a serious neurologic disorder.

          -  A patient with high-grade pulmonary embolism or pulmonary hypertension.

          -  A patient with high-grade renal failure.

          -  A patient with multiple organ failure.

          -  Active infection (including endocarditis).

          -  Sepsis.

          -  Active hemorrhagic disease (e.g. gastrointestinal bleeding, injury).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigeru Uemura, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shonan Tobu Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hidemasa Oh, M.D., Ph.D.</last_name>
    <phone>+81-086-235-6506</phone>
    <email>hidemasa@okayama-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shinichi Ohtsuki, M.D., Ph.D.</last_name>
    <phone>+81-086-235-7250</phone>
    <email>tsuki33@me.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidemasa Oh, M.D., Ph.D.</last_name>
      <phone>+81-086-235-6506</phone>
      <email>hidemasa@okayama-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Shinichi Ohtsuki, M.D., Ph.D.</last_name>
      <phone>+81-086-235-7250</phone>
      <email>tsuki33@me.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hidemasa Oh, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, Hirai K, Fukushima Y, Baba K, Goto T, Horio N, Kobayashi J, Kuroko Y, Kotani Y, Arai S, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology: The PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial. Circ Res. 2017 Mar 31;120(7):1162-1173. doi: 10.1161/CIRCRESAHA.116.310253. Epub 2017 Jan 4.</citation>
    <PMID>28052915</PMID>
  </results_reference>
  <results_reference>
    <citation>Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, Oh H. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial. J Thorac Cardiovasc Surg. 2015 Nov;150(5):1198-1207, 1208.e1-2. doi: 10.1016/j.jtcvs.2015.06.076. Epub 2015 Jul 8.</citation>
    <PMID>26232942</PMID>
  </results_reference>
  <results_reference>
    <citation>Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, Okuyama M, Kobayashi J, Baba K, Arai S, Kawabata T, Yoshizumi K, Tateishi A, Kuroko Y, Iwasaki T, Sato S, Kasahara S, Sano S, Oh H. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015 Feb 13;116(4):653-64. doi: 10.1161/CIRCRESAHA.116.304671. Epub 2014 Nov 17.</citation>
    <PMID>25403163</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 23, 2017</last_update_submitted>
  <last_update_submitted_qc>April 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Okayama University</investigator_affiliation>
    <investigator_full_name>Hidemasa Oh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

